Patent · US Active

TLR7/8 antagonists and uses thereof

US10947213B1 · kind B1 · utility

3Cited by
2References
10Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 28, 2020
Grant dateMar 16, 2021
Priority date—
Expiry dateApr 28, 2040

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D487/04
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Compounds of Formula 1 and pharmaceutically acceptable compositions thereof are useful as TLR7/8 antagonists.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.